A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia

Trial Profile

A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Chronic myelomonocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors Kura Oncology
  • Most Recent Events

    • 14 Mar 2017 According to a Kura Oncology media release, data expected during the first half of 2018.
    • 17 Jan 2017 According to Kura Oncology media release, first patient has been dosed in this study.
    • 20 Oct 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top